Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy | Lung Cancer | Small Cell Lung Cancer | USA Health